我武生物(300357.SZ):黃花蒿花粉變應原舌下滴劑新增兒童適應症獲受理
格隆匯2月8日丨我武生物(300357.SZ)公佈,日前,公司獲得國家藥品監督管理局發出的《受理通知書》,由公司提交的“黃花蒿花粉變應原舌下滴劑”擴展兒童適應症人羣的藥品補充申請已獲得正式受理。
黃花蒿花粉變應原舌下滴劑(國藥準字S20210001)已經獲批的適應症為:本品是一種變應原提取物,作為特異性免疫治療用於經過敏原檢測為黃花蒿/艾蒿花粉過敏引起的變應性鼻炎(或伴有結膜炎)的成年患者。
該次藥品補充申請的目的為適應症適用人羣的變更,在成人的基礎上擴展至兒童,有望進一步提升本品的適應症適用人羣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.